Cited by 62Neuroinflammation and Neurodegeneration MechanismsAlzheimer's disease research and treatmentsParkinson's Disease Mechanisms and Treatments

In Vivo Assessment of Neuroinflammation in 4‐Repeat Tauopathies

Open access
Palleis, Carla, Sauerbeck, Julia, Beyer, Leonie, Harris, Stefanie, Schmitt, Julia, Morenas‐Rodriguez, Estrella, Finze, Anika, Nitschmann, Alexander +24 more·2021·Movement Disorders

Published version of a preprint

Abstract

Background: Neuroinflammation has received growing interest as a therapeutic target in neurodegenerative disorders, including 4‐repeat tauopathies. Objectives: The aim of this cross‐sectional study was to investigate 18 kDa translocator protein positron emission tomography (PET) as a biomarker for microglial activation in the 4‐repeat tauopathies corticobasal degeneration and progressive supranuclear palsy. Methods: Specific binding of the 18 kDa translocator protein tracer 18 F‐GE‐180 was determined by serial PET during pharmacological depletion of microglia in a 4‐repeat tau mouse model. The 18 kDa translocator protein PET was performed in 30 patients with corticobasal syndrome (68 ± 9 years, 16 women) and 14 patients with progressive supranuclear palsy (69 ± 9 years, 8 women), and 13 control subjects (70 ± 7 years, 7 women). Group comparisons and associations with parameters of disease progression were assessed by region‐based and voxel‐wise analyses. Results: Tracer binding was significantly reduced after pharmacological depletion of microglia in 4‐repeat tau mice. Elevated 18 kDa translocator protein labeling was observed in the subcortical brain areas of patients with corticobasal syndrome and progressive supranuclear palsy when compared with controls and was most pronounced in the globus pallidus internus, whereas only patients with corticobasal syndrome showed additionally elevated tracer binding in motor and supplemental motor areas. The 18 kDa translocator protein labeling was not correlated with parameters of disease progression in corticobasal syndrome and progressive supranuclear palsy but allowed sensitive detection in patients with 4‐repeat tauopathies by a multiregion classifier. Conclusions: Our data indicate that 18 F‐GE‐180 PET detects microglial activation in the brain of patients with 4‐repeat tauopathy, fitting to predilection sites of the phenotype. The 18 kDa translocator protein PET has a potential for monitoring neuroinflammation in 4‐repeat tauopathies. © 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/mds.28395

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. F] GE-180: a blocking study using XBD173 in multiple sclerosis normal appearing white and grey matter. Mol Imag Biol 2019;21 (5):935-944.

Cited by

Sorted by citations

Authors
Palleis, C., Sauerbeck, J., Beyer, L., Harris, S., Schmitt, J., Morenas‐Rodriguez, E., Finze, A., Nitschmann, A., Ruch‐Rubinstein, F., Eckenweber, F., Biechele, G., Blume, T., Shi, Y., Weidinger, E., Prix, C., Bötzel, K., Danek, A., Rauchmann, B., Stöcklein, S., Lindner, S., Unterrainer, M., Albert, N. L., Wetzel, C., Rupprecht, R., Rominger, A., Bartenstein, P., Herms, J., Perneczky, R., Haass, C., Levin, J., Höglinger, G. U., & Brendel, M.
Affiliations
  • LMU Klinikum (DE)
  • German Center for Neurodegenerative Diseases Munich Germany
  • Department of Nuclear Medicine University Hospital of Munich, LMU Munich Munich Germany
  • German Center for Neurodegenerative Diseases (DE)
  • Department of Radiology University Hospital of Munich, LMU Munich Munich Germany
  • University of Regensburg (DE)
  • University of Bern (CH)
Corresponding author
  • Levin, Johannes
  • Höglinger, Günter U.
  • Brendel, Matthias
Venue
Movement Disorders
Publisher
Wiley
Published
2020-11-27
Volume
36
Issue
4
Pages
883-894
ISSN
  • 0885-3185 (ISSN-L)
  • 1531-8257
OpenAlex
W3108185411
Cited by
62
References
49
Citations by year
2026: 9 · 2025: 9 · 2024: 11 · 2023: 12 · 2022: 9 · 2021: 12
FWCI
3.19
Type
journal article
Language
en
Open access
Locations
  • Movement Disorders (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Open access LMU (Ludwid Maxmilian's Universitat Munchen) (submittedVersion, cc-by-nc)
Funders
  • Deutsche Forschungsgemeinschaft (421887978, 422182557, BR4580/1‐1, EXC 2145 SyNergy ‐ ID 390857198, RO5194/1‐1)
  • Deutsches Zentrum für Neurodegenerative Erkrankungen (DescribePSP Study)
  • NOMIS Stiftung (FTLD project)
Topics
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
Keywords
neuroinflammation, translocator protein (TSPO), microglial activation, corticobasal degeneration, progressive supranuclear palsy, microglial depletion, disease progression biomarkers, globus pallidus internus
MeSH terms
Aged, Alzheimer Disease, Animals, Brain, Cross-Sectional Studies, Female, Humans, Male, Middle Aged, Supranuclear Palsy, Progressive, tau Proteins, Tauopathies, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review